Sensus Healthcare, Inc.
Business Overview: Sensus Healthcare, Inc. (NASDAQ: SRTS)
Executive Summary
Sensus Healthcare is a Boca Raton, Florida-based medical device company focused on non-invasive superficial radiation therapy (SRT) for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. As of December 31, 2025, Sensus had installed 955 SRT units in 21 countries, operating as a single business segment.
The company's model increasingly blends equipment sales with recurring revenue — service contracts, a revenue-share "Fair Deal Agreement" structure, and newly launched financial services and cloud software (Sensus Link) introduced in February 2026 — layered onto its core capital-equipment business.
1. Core Business Model & How They Work
[ Sell/Finance SRT-100 Family Systems to Dermatology & Radiation Oncology Practices ] ➡️ [ Install & Train ] ➡️ [ Recurring Service Contracts (Sentinel Program) ] ➡️ [ Consumables/Shielding Sales ]
Alternative path: ➡️ [ Fair Deal Agreement Revenue-Share ]2. Business Segments
Sensus operates as a single reportable segment: SRT-based medical devices and associated services for dermatology, radiation oncology, and plastic surgery/aesthetic markets.
3. Product Portfolio
| Product | Category | Purpose | Why It Matters |
|---|---|---|---|
| SRT-100 | Capital equipment | Base superficial radiation therapy system | Core platform; a no-anesthesia alternative to surgery for NMSC/keloids |
| SRT-100 Vision | Capital equipment | Adds treatment planning + embedded ultrasound imaging | Premium tier with better dosimetry/documentation |
| SRT-100+ | Capital equipment | Expanded energy range, remote diagnostics, new X-ray tube | Top-tier system for higher-acuity use cases |
| Sentinel Service Program | Recurring service | Parts/labor coverage, annual maintenance | Recurring revenue layered on equipment sales |
| Fair Deal Agreement | Revenue-share model | Sensus supplies system + technologist + physics oversight for a % of reimbursements | Lowers adoption barriers for practices, aligns Sensus incentives with utilization |
| Sensus Healthcare Financial Services / Sensus Link | New (Feb. 2026) | Third-party financing; cloud SRT software | Expands recurring/financing revenue beyond hardware sales |
4. Competitive Landscape
Item 1's Competition section names no specific competitors; it frames competition against alternative treatment methods for the same conditions — linear accelerator-based radiation treatment is explicitly cited as the main alternative for radiation oncologists, alongside surgical options more broadly in the NMSC/keloid treatment landscape. Competitive factors cited: clinical outcomes, physician/patient acceptance, ease of use/reliability, price/reimbursement eligibility, technical leadership, marketing/distribution, speed to market, and customer service.
5. Strategic Strengths & Risks
Strengths: non-invasive, no-anesthesia SRT is a genuine differentiator versus surgical alternatives for sensitive head/neck NMSC cases, appealing to both physicians and patients; the Fair Deal Agreement revenue-share model lowers the capital barrier for smaller dermatology practices to adopt the technology while giving Sensus a recurring, utilization-linked revenue stream; diversifying into financing (Sensus Healthcare Financial Services) and software (Sensus Link) layers higher-margin, stickier revenue onto a historically hardware-centric business.
Risks: a single-segment, single-core-technology business is concentrated risk if reimbursement policy for superficial radiation therapy shifts unfavorably; competes against the well-established linear-accelerator radiation oncology infrastructure and surgical standard-of-care, both deeply entrenched; a small installed base (955 units in 21 countries) relative to global NMSC incidence suggests substantial unmonetized market but also limited current scale versus larger medical device peers.
6. Financial Overview
| Metric | SRTS Profile | Context |
|---|---|---|
| Installed Base | 955 units, 21 countries (as of Dec. 31, 2025) | Mostly U.S.-concentrated; room to expand internationally |
| Business Model Mix | Direct equipment sales + Fair Deal revenue-share + service contracts | Diversifying toward recurring revenue |
| New Offerings (Feb. 2026) | Sensus Healthcare Financial Services, Sensus Link | Financing + cloud software extend the revenue model |
| Segment Structure | Single reportable segment | Entire business concentrated in SRT technology |
7. Summary Conclusion
Sensus Healthcare has built a real, if narrow, clinical niche in non-invasive skin cancer and keloid treatment, differentiated from both surgery and traditional linear-accelerator radiation oncology. Its recent push into financing and software suggests management is trying to broaden the business's revenue mix and stickiness beyond one-time capital equipment sales, but the company's fortunes remain tightly tied to the adoption curve of a single core technology platform.